Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy

Expert Review of Vaccines

Volumn 15, Issue 2, 2016, Pages 239-256

  Ling, Juejing ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

anti TNF therapy; biologicals; immune system; Immunoglobulins; infection; newborn; prenatal exposure; rituximab; vaccination

Indexed keywords

ABATACEPT; ADALIMUMAB; BCG VACCINE; BELATACEPT; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ETANERCEPT; GOLIMUMAB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; NATALIZUMAB; PNEUMOCOCCUS VACCINE; RITUXIMAB; ROTAVIRUS VACCINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; BIOLOGICAL PRODUCT; VACCINE;

ANTIBODY RESPONSE; BREAST MILK; DRUG HALF LIFE; DRUG TRANSPORT; DRUG WITHDRAWAL; FOLLOW UP; GESTATIONAL AGE; HOUSEHOLD CONTACT; HUMAN; IMMUNE SYSTEM; INFANT; MISCELLANEOUS NAMED GROUPS; NEWBORN; OUTCOME ASSESSMENT; PLACENTAL TRANSFER; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; TREATMENT WITHDRAWAL; VACCINATION; FEMALE; IMMUNOLOGY; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT FAILURE;

BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT FAILURE; VACCINES;

EID: 84955651288     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1115351     Document Type: Review

References (83)

1. Papers of special note have been highlighted as
2. of interest
3. of considerable interest
4. Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc [Internet]. 2004; 1 (4): 24-29. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3564302&tool=pmcentrez&rendertype=abstract
5. Malviya G, Salemi S, Bruno L., et al. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs. 2013; 27 (4): 329-345
6. Nielsen OH, Jess T. IBD: can TNF inhibitors be administered during the third trimester? Nat Rev Gastroenterol Hepatol [Internet]. 2013; 10 (3): 130-131. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23247511
7. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol [Internet]. 2013; 19 (17): 2591-2602. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3645377&tool=pmcentrez&rendertype=abstract
8. Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med [Internet]. 2013; 11 (1): 174. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3734216&tool=pmcentrez&rendertype=abstract
9. Mahadevan U, Wolf DC, Dubinsky M., et al. Placental transfer of anti-Tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol [Internet]. 2013; 11 (3): 286-292. 10.1016/j.cgh.2012.11.011
10. Zelinkova Z, De Haar C, De Ridder L., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011; 33 (9): 1053-1058
11. Palmeira P, Quinello C, Silveira-Lessa AL., et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012; 2012:1-13. Article ID 985646. 10.1155/2012/985646
12. Guiddir T, Fremond M-L, Triki TB., et al. Anti-TNF-Â therapy may cause neonatal neutropenia. Pediatrics [Internet]. 2014; 134 (4): e1189-e1193. Available from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-0054
13. Cheent K, Nolan J, Shariq S., et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohns Disease. J Crohns Colitis. 2010; 4 (5): 603-605
14. Malek A. Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy. Expert Rev Clin Immunol [Internet]. 2013; 9 (3): 235-249
15. Dancis J, Lind J, Oratz M., et al. Placental transfer of proteins in human gestation. Am J Obstet Gynecol. 1961; 82: 167-171
16. Saji F, Samejima Y, Kamiura S., et al. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999; 4 (2): 81-89
17. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol [Internet]. 2009; 104 (1): 228-233
18. Vasiliauskas EA, Church JA, Silverman N., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006; 4 (10): 1255-1258
19. Fritzsche J, Pilch A, Mury D., et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012; 46 (8): 718-719
20. Ben-Horin S, Yavzori M, Kopylov U., et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011; 5 (6): 555-558
21. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008; 14 (19): 3085-3087
22. Julsgaard M, Brown S, Gibson P., et al. Adalimumab levels in an infant. J Crohns Colitis [Internet]. 2013; 7 (7): 597-598. 10.1016/j.crohns.2012.10.009
23. Ben-Horin S, Yavzori M, Katz L., et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol [Internet]. 2010; 8 (5): 475-476. 10.1016/j.cgh.2009.11.023
24. Murashima A, Watanabe N, Ozawa N., et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infants serum. Ann Rheum Dis [Internet]. 2009; 68 (11): 1793-1794
25. Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT., et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010; 49 (11): 2225-2227
26. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol. 2004; 31 (5): 1017
27. Friedrichs B, Tiemann M, Salwender H., et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica [Internet]. 2006; 91 (10): 1426-1427. Available from: http://www.haematologica.org/content/91/10/1426.abstract
28. Haghikia A, Langer-Gould A, Rellensmann G., et al Natalizumab use during the third trimester of pregnancy. JAMA Neurol [Internet]. 2014; 71 (7): 1-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24821217
29. de Lima A, Zelinkova Z, van der Ent C., et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut [Internet]. 2015; 1-8. Available from: http://gut.bmj.com/cgi/doi/10.1136/gutjnl-2015-309321
30. Mahadevan U, Kane SV, Church JA., et al. 499 the effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology [Internet]. 2008; 134 (4): A-69. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508508603236
31. Steenholdt C, Ai-Khalaf M, Ainsworth MA., et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis [Internet]. 2012; 6 (3): 358-361. 10.1016/j.crohns.2011.10.002
32. Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci [Internet]. 2014; 1317: 32-38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24840548
33. Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero. Gastroenterology [Internet]. 2011; 140 (5): S61-S62. Available from: http://www.sciencedirect.com/science/article/pii/S0016508511602515
34. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-? Monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007; 58 (2): 138-149
35. Decker M, Rothermundt C, Holländer G., et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006; 7 (8): 693-694
36. Klink DT, Van Elburg RM, Schreurs MWJ., et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008; 2008:1-6. Article ID 271363. 10.1155/2008/271363
37. Ojeda-Uribe M, Afif N, Dahan E., et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013; 32 (5): 695-700
38. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013; 108 (April): 1426-1438
39. Julsgaard M, Christensen LA, Gibson PR., et al. Adalimumab and Infliximab levels in neonates correlate with duration of treatment in pregnancy (ERA study). J Gastroenterol Hepatol. 2014; 29: 117-118
40. Zelinkova Z, van der Ent C, Bruin KF., et al. Effects of discontinuing anti-Tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol [Internet]. 2012; 11 (3): 318-321. 10.1016/j.cgh.2012.10.024
41. Mahadevan U, Martin CF, Dubinsky M., et al. 960 exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology [Internet]. 2014; 146 (5): S-170. Available from: http://www.gastrojournal.org/article/S0016508514606028/fulltext
42. Arsenescu R, Arsenescu V, de Villiers WJS. TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol [Internet]. 2011; 106 (4): 559-562. 10.1038/ajg.2011.5
43. Djokanovic N, Klieger-Grossmann C, Pupco A., et al. Safety of infliximab use during pregnancy. Reprod Toxicol [Internet]. 2011; 32 (1): 93-97
44. Johnsson A, Avlund S, Grosen A., et al. Chicken pox infection in a three months old infant exposed in utero to Adalimumab. J Crohns Colitis [Internet]. 2013; 7 (3): e116-e117. 10.1016/j.crohns.2012.07.020
45. Roux CH, Brocq O, Breuil V., et al. Pregnancy in rheumatology patients exposed to anti-Tumour necrosis factor (TNF)-Alpha therapy. Rheumatology [Internet]. 2007; 46 (4): 695-698
46. Seirafi M, de Vroey B, Amiot A., et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2014; 40 (4): 363-373. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24980270
47. Seirafi M, Treton X, Vroey BD., et al. Anti-TNF therapy and pregnancy in inflammatory bowel disease: a prospective cohort study from the GETAID. Gastroenterology [Internet]. 2011; 140 (5): S-175. 10.1016/S0016-5085(11)60708-7
48. Bortlik M, Duricova D, Machkova N., et al. Impact of anti-Tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-Term outcome of exposed children. Inflamm Bowel Dis [Internet]. 2014; 20 (3): 495-501. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24407486
49. Mahadevan U, Martin CF, Sandler RS., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology [Internet]. 2012; 142 (5): S-149. Available from: http://www.gastrojournal.org/article/S0016508512605617/fulltext
50. Bessissow T, Renard M, Hoffman I., et al. Review article: non-malignant haematological complications of anti-Tumour necrosis factor alpha therapy. Aliment Pharmacol Ther [Internet]. 2012; 36 (4): 312-323. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22725726
51. Liu JH, Wei S, Lamy T., et al. Chronic neutropenia mediated by fas ligand. Blood [Internet]. 2000; 95 (10): 3219-3222. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10807792
52. Coakley G, Iqbal M, Brooks D., et al. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Feltys and large granular lymphocyte syndromes. Arthritis Rheum. 2010; 43 (4): 834
53. Keystone EC. Tumor necrosis factor-Alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am [Internet]. 2001; 27 (2): 427-443. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11396102
54. Ton E, Tekstra J, Hellmann PM., et al. Safety of rituximab therapy during twins pregnancy. Rheumatology. 2011; 50 (4): 806-808
55. Gall B, Yee A, Berry B., et al. Rituximab for management of refractory pregnancy-Associated immune thrombocytopenic purpura. J Obs Gynaecol Can. 2010; 32 (12): 1167-1171
56. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2011; 19 (14): 3438-3442
57. Martínez-Martínez MU, Baranda-Cándido L, González-Amaro R., et al. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatol (United Kingdom). 2013; 52 (2): 405-406
58. Mandal PK, Dolai TK, Bagchi B., et al. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr. 2014; 81 (October): 1092-1094
59. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol [Internet]. 2004; 72 (4): 292-295. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15089769
60. Pellkofer HL, Suessmair C, Schulze A., et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009; 15 (8): 1006-1008
61. Ponte P, Lopes MJP. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol. 2010; 63 (2): 355-356
62. Ringelstein M, Harmel J, Distelmaier F., et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler [Internet]. 2013; 19 (11): 1544-1547. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23886825
63. Pendergraft WF, McGrath MM, Murphy AP., et al. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis [Internet]. 2013; 72 (12): 2051-2053. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23864238
64. Ojeda-Uribe M, Gilliot C, Jung G., et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol. 2006; 26 (4): 252-255
65. Chakravarty E, Langen E, Druzin M., et al. High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Obstet Gynecol Conf [Internet]. 2011; 204 (1 Suppl)
66. Wehner NG, Shopp G, Osterburg I., et al. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol [Internet]. 2009; 86 (2): 144-156. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19283860
67. Slatter MA, Gennery AR. Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol. 2008; 152 (3): 389-396
68. Atkinson AR, Roifman CM. Low serum immunoglobulin G2 levels in infancy can be transient. Pediatrics. 2007; 120 (3): e543-e547
69. Johnson D, Luo Y, Jones KL., et al. Pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in pregnancy project. Arthritis Rheum Conf Annu Sci Meet Am Coll Rheumatol Assoc Rheumatol Heal Prof [Internet]. 2011; 63 (10 Suppl. 1)
70. van der Woude CJ, Ardizzone S, Bengtson MB., et al. The second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis [Internet]. 2014; 9 (2): 107-124. Available from: http://ecco-jcc.oxfordjournals.org/cgi/doi/10.1093/ecco-jcc/jju006
71. Mahadevan U, Cucchiara S, Hyams JS., et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohns and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol [Internet]. 2011; 106 (2): 214-23; quiz 224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21157441
72. Akinsanya-Beysolow I.,. on Immunization Practices (ACIP) AC, Group ACIW, for Disease Control C, (CDC) P. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2014. MMWR Morbidity Mortal Wkly Rep. 2014; 63 (5): 108-109
73. Canada PHA. Canadian immunization guide (online). 2015. Jun 13
74. Moses J, Alkhouri N, Shannon A., et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol [Internet]. 2012; 107 (1): 133-138. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21876562
75. Fiore AE, Uyeki TM, Broder K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep [Internet]. 2010; 59 (RR-8): 1-62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20689501
76. Woerner A, Sauvain M-J, Aebi C., et al. Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-α inhibitors. Hum Vaccin. 2011; 7 (12): 1293-1298
77. Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y) [Internet]. 2014; 10 (6): 355-363. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4080872&tool=pmcentrez&rendertype=abstract
78. Publication WHO. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine. 2010; 28 (3): 589-590
79. Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J [Internet]. 2012; 12 (3): 228-243. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3448245&tool=pmcentrez&rendertype=abstract
80. Avanzini MA, Carra AM, Maccario R., et al. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. J Clin Immunol. 1998; 18 (3): 193-201
81. Rubin LG, Levin MJ, Ljungman P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58 (3): 309-318
82. Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J [Internet]. 2012; 12 (3): 228-243. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3448245&tool=pmcentrez&rendertype=abstract
83. Tamma P. Vaccines in immunocompromised patients. Pediatr Rev [Internet]. 2010; 31 (1): 38-40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20048039